---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-009115"
form_type: "8-K"
ticker: "GYRE"
cik: "0001124105"
company_name: "GYRE THERAPEUTICS, INC."
filed_at: "2026-03-12T23:59:59+00:00"
generated_at: "2026-05-15T12:55:45.935465+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "medium"
source: SEC EDGAR
---

# Gyre Therapeutics projects $400-600M in F351 revenue within 5 years; provides Cullgen TRK degrader update

## Summary
- Company sees potential $400-600M revenue for Hydronidone (F351) in liver fibrosis within 5 years.
- Expects ETUARY for lung fibrosis to sustain ~$100M absent near-term generic competition.
- Sees 20-25% net margins for commercial products; favorable R&D tax deductibility in Beijing/Shanghai campuses.
- Cullgen's TRK degrader CG001419 Phase 2 pain trial enrolling at doses expected to show ~95% TRK degradation.
- Cullgen's degrader antibody conjugates (DAC) show ~10-100x potency vs standalone degrader in vitro/animal models.

## SEC filing metadata
- accession: 0001140361-26-009115
- form_type: 8-K
- ticker: GYRE
- cik: 0001124105
- company_name: GYRE THERAPEUTICS, INC.
- filed_at: 2026-03-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: medium
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1124105/000114036126009115/0001140361-26-009115-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1124105/000114036126009115/ef20067723_form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-009115
- JSON: https://secwatch.observer/filing/0001140361-26-009115.json
- Plain text: https://secwatch.observer/filing/0001140361-26-009115.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.